Lilly’s 3Q Revenues up 18%

Lilly
3Q Revenues: $6.8 billion (+18%)
3Q Earnings: $1.1 billion (-8%)
YTD Revenues: $20.3 billion (+19%)
YTD Earnings: $3.9 billion (-5%)
Comments:  Key growth products, consisting of Trulicity, Taltz, Verzenio, Jardiance, Emgality, Olumiant, Tyvyt, Retevmo and Cyramza, contributed 17 percentage points of revenue growth and represented approximately 58 percent of total revenue in the third quarter, excluding revenue from COVID-19 therapies. COVID-19 antibodies sales were $217.1 million in the quarter. Revenue from Trulicity, Taltz, Verzenio and Emgality each grew by more than 30 percent versus prior year. Trulicity sales were $1.6 billion up 45% in the quarter. Humalog sales were down 5% to $626.7 million. Alimta sales were down 21% to $457 million. Taltz sales were $593.1 million, up 30%. Jardiance sales were $390.4 million, up 26%. Verzenio sales were $335.5 million, up 43%. Humulin sales were down 6% to $286.7 million. Olumiant sales reached $406.9 million.
 
Filings
The FDA approved Verzenio as the first and only CDK4/6 inhibitor for certain people with HR+ HER2- high risk early breast cancer.
 
The FDA approved a new indication for Erbitux in combination with Braftovi for the treatment of certain adult patients with metastatic colorectal cancer with a BRAF V600E mutation.
 
The FDA expanded the Emergency Use Authorization for bamlanivimab and etesevimab administered together to include post-exposure prophylaxis in certain individuals for the prevention of SARS-CoV-2 infection.
 
Jardiance was approved by the FDA to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF).